Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBO-11818 in Advanced KRAS Mutant Cancers
NCT06917079Phase 1Recruiting
- Sponsor
- TheRas, Inc.
- Start
- Mar 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of BBO-11818 in non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC) and 1 more (20 cohorts), sponsored by TheRas, Inc. Primary endpoints: Incidence and severity of treatment emergent adverse events (TEAEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs) at 5 years and Recommended dose of BBO-11818 in combination therapies at 5 years. Started Mar 2025; status: recruiting.
02
Drugs
BBO-11818
03
Conditions
non-small cell lung cancer (NSCLC)pancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT06917079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06917079.